Moleculin Biotech raises ~$6.8M via warrant exercise inducement, issues new Series G warrants

Moleculin Biotech, Inc.

Entered inducement letters with holders of Series C/D/F warrants to exercise at $6.63 or $6.3219 per share.
Company expects aggregate gross proceeds of up to ~$6.8M from the warrant exercises.
In exchange, issues new Series G warrants to purchase up to 2,610,823 shares (250% of exercised shares) at $6.63, exercisable upon shareholder approval, 5-year term.
New warrants include anti-dilution price reset with a floor of $1.326 per share and cashless exercise feature.
Company to file resale registration statement for Series G warrant shares by Jan 8, 2026, seek SEC effectiveness by Feb 9, 2026.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.95

Moleculin Biotech, Inc. issued 250% of the number of shares of Company common stock underlying the exercised Existing Warrants, comprised of new Series G warrants to purchase up to 2,610,823 of warrant to holders of existing Series C warrants, Series D warrants and Series F warrants for aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants.

Security: warrant
Shares: 250% of the number of shares of Company common stock underlying the exercised Existing Warrants, comprised of new Series G warrants to purchase up to 2,610,823
Purchaser: holders of existing Series C warrants, Series D warrants and Series F warrants
Consideration: aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants

Exact text from the filing

registration statements on Form S-1 (File No. 333-286276) and Form S-3 (File No. 333-290418). The Company anticipates receiving aggregate gross proceeds of up to approximately $6.8 million from the exercise of the Existing Warrants before deducting fees and other expenses payable by it. Each Inducement Warrant has an exercise price of $6.63 per share, will be

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Moleculin Biotech, Inc. entered into Inducement Letters with holders of existing Series C, Series D, and Series F warrants valued at up to approximately $6.8 million (effective 2025-12-09).

Action: entry
Agreement: equity purchase
Counterparty: holders of existing Series C, Series D, and Series F warrants
Value: up to approximately $6.8 million
Effective: 2025-12-09

Exact text from the filing

On December 9, 2025, Moleculin Biotech, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with: (i) the holder of existing Series C warrants and Series D warrants to purchase an aggregate of up to 727,969 shares of Company common stock

View on SEC.gov

Browse all equity issuances →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-037414

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.